Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 318-327, June 2010

Targets for cancer therapy in childhood sarcomas

University Children’s Hospital, Department of Oncology, Steinwiesstrasse 75, CH-8032 Zürich, Switzerland

published online 11 March 2010.

Summary 

Development of chemotherapeutic treatment modalities resulted in a dramatic increase in the survival of children with many types of cancer. Still, in case of some pediatric cancer entities including rhabdomyosarcoma, osteosarcoma and Ewing’s sarcoma, survival of patients remains dismal and novel treatment approaches are urgently needed. Therefore, based on the concept of targeted therapy, numerous potential targets for the treatment of these cancers have been evaluated pre-clinically or in some cases even clinically during the last decade. This review gives an overview over many different potential therapeutic targets for treatment of these childhood sarcomas, including receptor tyrosine kinases, intracellular signaling molecules, cell cycle and apoptosis regulators, proteasome, hsp90, histone deacetylases, angiogenesis regulators and sarcoma specific fusion proteins. The large number of potential therapeutic targets suggests that improved comparability of pre-clinical models might be necessary to prioritize the most effective ones for future clinical trials.

Keywords: Osteosarcoma, Ewing’s sarcoma, Rhabdomyosarcoma, Targeted cancer therapy, Molecular targets

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(10)00027-7

doi:10.1016/j.ctrv.2010.02.007

Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 318-327, June 2010